According to a new report by MarketsandMarkets™, the apheresis market is projected to reach $3.9 billion by 2029, growing at a Compound Annual Growth Rate (CAGR) of 8.8% from 2024 to 2029. The market, estimated to be worth $2.6 billion in 2024, is driven by various factors such as the rise in demand for source plasma from biopharmaceutical companies, increasing demand for blood components, and favorable reimbursement for apheresis.
The report highlights the growth opportunities in the apheresis market, including investments from government bodies and leading players. However, strict donor recruitment criteria may restrain the market during the forecast period.
Based on procedure, therapeutic apheresis is the fastest-growing segment in the market. Therapeutic apheresis procedures offer effective treatment options for various medical conditions, including neurological disorders, renal diseases, leukemia, and metabolic disorders. As therapeutic benefits continue to be uncovered, healthcare providers are increasingly adopting apheresis as part of their treatment protocols.
With regards to application, photopheresis is the fastest-growing segment. Photopheresis provides targeted and personalized therapy for blood disorders such as graft-versus-host disease (GVHD), cutaneous T-cell lymphoma (CTCL), and autoimmune hemolytic anemia. Increased awareness of photopheresis benefits is driving its adoption and fueling growth in the market.
Hospitals and transfusion centers are the fastest-growing end users in the apheresis market. These institutions have the financial resources to afford centrifugation-based apheresis devices, allowing them to provide cutting-edge treatments and services to their patients.
North America dominates the global apheresis market, accounting for the largest share. The region’s rising incidences of surgical procedures and the demand for blood components for transfusion contribute to the market’s growth.
Key players in the apheresis market include Terumo BCT, Fresenius, Haemonetics, Baxter International, Asahi Kasei Medical, and Becton, Dickinson and Company, among others.
Overall, the apheresis market shows promising growth potential, driven by increasing demand and advancements in therapeutic techniques.
The apheresis market operates within the healthcare industry, specifically in the field of blood component separation and collection. Apheresis is a medical procedure that involves selectively removing blood components, such as plasma, platelets, or specific cells, from a donor’s blood and then returning the remaining components back to the donor.
The market forecast for the apheresis industry is positive, with a projected growth of $3.9 billion by 2029. This growth is attributed to several factors. Firstly, there is a rising demand for source plasma from biopharmaceutical companies, who use the plasma in the production of life-saving therapies. Additionally, the demand for blood components, including platelets and plasma, is increasing due to the growing prevalence of chronic diseases and surgeries.
Another contributing factor to the market’s growth is the favorable reimbursement policies for apheresis procedures. Healthcare providers are encouraged to offer apheresis services due to the availability of reimbursement, which in turn drives the adoption of apheresis procedures.
However, there are certain challenges that may hinder the market’s growth. Strict donor recruitment criteria can limit the availability of suitable donors for apheresis procedures. Donor eligibility requirements, such as age, weight, and health status, can restrict the pool of potential donors, thereby impacting the supply of blood components.
In terms of market segments, therapeutic apheresis is the fastest-growing segment. This is because therapeutic apheresis procedures have shown effectiveness in treating various medical conditions, such as neurological disorders, renal diseases, leukemia, and metabolic disorders. As healthcare providers continue to uncover the therapeutic benefits of apheresis, its adoption is expected to increase.
Among the different applications of apheresis, photopheresis is the fastest-growing segment. Photopheresis is a specialized form of apheresis that provides targeted and personalized therapy for blood disorders such as graft-versus-host disease (GVHD), cutaneous T-cell lymphoma (CTCL), and autoimmune hemolytic anemia. The increasing awareness of the benefits of photopheresis is driving its adoption and fueling growth in the market.
The fastest-growing end users in the apheresis market are hospitals and transfusion centers. These institutions have the financial resources to afford centrifugation-based apheresis devices, enabling them to offer advanced treatments and services to their patients.
North America currently dominates the global apheresis market, holding the largest market share. This is due to the region’s high prevalence of surgical procedures and the demand for blood components for transfusion. However, the market is expected to show growth opportunities in other regions as well, particularly in Asia Pacific and Europe, due to increasing healthcare expenditure and advancements in healthcare infrastructure.
Key players in the apheresis market include Terumo BCT, Fresenius, Haemonetics, Baxter International, Asahi Kasei Medical, and Becton, Dickinson and Company. These companies play a crucial role in driving innovation, research, and development in the field of apheresis.
Overall, the apheresis market holds promising growth potential, fueled by increasing demand for blood components, advancements in therapeutic techniques, and investments from government bodies and leading players. The market’s expansion is expected to benefit patients by providing improved treatment options for various medical conditions.